Book contents
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Reviews
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Copyright page
- Contents
- Foreword
- Abbreviations
- Introduction
- Amantadine
- Amitriptyline
- Apomorphine Hydrochloride Subcutaneous Infusion
- Apomorphine Hydrochloride Subcutaneous Injection
- Apomorphine Hydrochloride Sublingual Film
- Botulinum Toxin
- Citalopram
- Clonazepam
- Clozapine
- Desipramine
- Domperidone
- Donepezil
- Droxidopa
- Entacapone
- Fludrocortisone
- Glycopyrrolate
- Istradefylline
- Levodopa–Benserazide
- Levodopa–Carbidopa
- Levodopa–Carbidopa Intestinal Gel
- Levodopa–Carbidopa–Entacapone Intestinal Gel
- Levodopa, Inhaled
- Lubiprostone
- Macrogol
- Melatonin
- Memantine
- Midodrine
- Mirabegron
- Mirtazapine
- Modafinil
- Naltrexone
- Nortriptyline
- Opicapone
- Oxybutynin
- Pimavanserin
- Piribedil
- Pramipexole*
- Quetiapine
- Rasagiline
- Rivastigmine
- Ropinirole
- Rotigotine
- Safinamide
- Selegiline
- Sildenafil
- Solifenacin
- Tolcapone
- Tolterodine
- Trihexyphenidyl
- Venlafaxine
- Zonisamide
- Levodopa Dose Equivalence in Parkinson’s
- Subcutaneous Foslevodopa Foscarbidopa infusion
- Index
- References
Ropinirole
Published online by Cambridge University Press: 20 February 2025
Book contents
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Reviews
- The Movement Disorders Prescriber’s Guide to Parkinson’s Disease
- Copyright page
- Contents
- Foreword
- Abbreviations
- Introduction
- Amantadine
- Amitriptyline
- Apomorphine Hydrochloride Subcutaneous Infusion
- Apomorphine Hydrochloride Subcutaneous Injection
- Apomorphine Hydrochloride Sublingual Film
- Botulinum Toxin
- Citalopram
- Clonazepam
- Clozapine
- Desipramine
- Domperidone
- Donepezil
- Droxidopa
- Entacapone
- Fludrocortisone
- Glycopyrrolate
- Istradefylline
- Levodopa–Benserazide
- Levodopa–Carbidopa
- Levodopa–Carbidopa Intestinal Gel
- Levodopa–Carbidopa–Entacapone Intestinal Gel
- Levodopa, Inhaled
- Lubiprostone
- Macrogol
- Melatonin
- Memantine
- Midodrine
- Mirabegron
- Mirtazapine
- Modafinil
- Naltrexone
- Nortriptyline
- Opicapone
- Oxybutynin
- Pimavanserin
- Piribedil
- Pramipexole*
- Quetiapine
- Rasagiline
- Rivastigmine
- Ropinirole
- Rotigotine
- Safinamide
- Selegiline
- Sildenafil
- Solifenacin
- Tolcapone
- Tolterodine
- Trihexyphenidyl
- Venlafaxine
- Zonisamide
- Levodopa Dose Equivalence in Parkinson’s
- Subcutaneous Foslevodopa Foscarbidopa infusion
- Index
- References
Summary
Ropinirole hydrochloride (4-[2-(dipropylamino)ethyl]-2-indolinone hydrochloride) is a white to yellow solid, with a molecular weight of 296.8 and an empirical formula of C16H24N2O,HCl.
- Type
- Chapter
- Information
- The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 411 - 423Publisher: Cambridge University PressPrint publication year: 2025
References
Suggested Reading
Binde, CD, Tvete, IF, Gåsemyr, JI, Natvig, B, Klemp, M. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis. Eur J Clin Pharmacol 2020; 76(12): 1731–1743.CrossRefGoogle ScholarPubMed
Mizuno, Y, Nomoto, M, Hasegawa, K, Hattori, N, Kondo, T, Murata, M, Takeuchi, M, Takahashi, M, Tomida, T ; Rotigotine Trial Group. Rotigotine vs ropinirole in advanced stage Parkinson’s disease: a double-blind study. Parkinsonism Relat Disord 2014;. 20(12): 1388–1393.CrossRefGoogle ScholarPubMed
Pahwa, R, Stacy, MA, Factor, SA, Lyons, KE, Stocchi, F, Hersh, BP, Elmer, LW, Truong, DD, Earl, NL ; EASE-PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68(14): 1108–1115.CrossRefGoogle ScholarPubMed
Rektorova, I, Balaz, M, Svatova, J, Zarubova, K, Honig, I, Dostal, V, Sedlackova, S, Nestrasil, I, Mastik, J, Bares, M, Veliskova, J, Duseck, L. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol 2008; 31(5): 261–266.CrossRefGoogle ScholarPubMed
Watts, RL, Lyons, KE, Pahwa, R, Sethi, K, Stern, M, Hauser, RA, Olanow, W, Gray, AM, Adams, B, Earl, NL ; 228 Study Investigators. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov Disord 2010; 25(7): 858–866.CrossRefGoogle ScholarPubMed
References
Agüera-Ortiz, L, García-Ramos, R, Pérez, FLG, López-Álvarez, J, Rodríguez, JMM, Rodríguez, FJO, Pueyo, JO, Valero, CP, Porto-Etessam, J. Focus on depression in Parkinson’s disease: a Delphi consensus of experts in psychiatry, neurology, and geriatrics. Parkinsons Dis 2021; 2021: 6621991.Google ScholarPubMed
AHFS Drug information, 2012. Bethesda: American Society of Health-System Pharmacists. Accessed on 23 June 2022 via www.medicinescomplete.com.Google Scholar
Dusek, P, Busková, J, Ru˚zicka, E, Majerová, V, Srp, A, Jech, R, Roth, J, Sonka, K. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. Clin Neuropharmacol 2010; 33(4): 186–190.CrossRefGoogle ScholarPubMed
Gershon, AA, Amiaz, R, Shem-David, H, Grunhaus, L. Ropinirole augmentation for depression: a randomized controlled trial pilot study. J Clin Psychopharmacol 2019; 39(1): 78–81.CrossRefGoogle ScholarPubMed
Joint Formulary Committee. British National Formulary (online). London: BMJ Group and Pharmaceutical Press. Accessed on 23 June 2022 via www.medicinescomplete.com.Google Scholar
Koschel, J, Chaudhuri, KR, Tönges, L, Thiel, M, Raeder, V, Jost, WH. Implications of dopaminergic medication withdrawal in Parkinson’s disease. J Neural Transm (Vienna) 2022; 129(9): 1169–1178.CrossRefGoogle ScholarPubMed
Latt, MD, Lewis, S, Zekry, O, Fung, VSC. Factors to consider in the selection of dopamine agonists for older persons with Parkinson’s disease. Drugs Aging 2019; 36(3): 189–202.CrossRefGoogle ScholarPubMed
Okano, H, Yasuda, D, Fujimori, K, Morimoto, S, Takahashi, S. Ropinirole, a new ALS drug candidate developed using iPSCs. Trends Pharmacol Sci 2020; 41(2): 99–109.CrossRefGoogle ScholarPubMed
Ray Chaudhuri, K, Martinez-Martin, P, Rolfe, KA, Cooper, J, Rockett, CB, Giorgi, L, Ondo, WG. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol 2012; 19(1): 105–113.CrossRefGoogle ScholarPubMed
Ropinirole. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 23 June 2022 via www.medicinescomplete.com.Google Scholar
Ropinirole. In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Accessed on 23 June 2022 via www.micromedexsolutions.com.Google Scholar
Rota, S, Boura, I, Batzu, L, Titova, N, Jenner, P, Falup-Pecurariu, C, Chaudhuri, KR. “Dopamine agonist phobia” in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine. Expert Rev Neurother 2020; 20(9): 953–965.CrossRefGoogle ScholarPubMed
Schmitz, JM, Suchting, R, Green, CE, Webber, HE, Vincent, J, Moeller, FG, Lane, SD. The effects of combination levodopa-ropinirole on cognitive improvement and treatment outcome in individuals with cocaine use disorder: a Bayesian mediation analysis. Drug Alcohol Depend 2021; 225: 108800.CrossRefGoogle ScholarPubMed
Summary of Product Characteristics – Requip XL 4 mg prolonged-release tablets. GlaxoSmithKline UK. Electronic Medicines Compendium: Requip XL 4 mg prolonged-release tablets – summary of product characteristics (SmPC) – (emc). Accessed on 23 June 2022 via www.medicines.org.uk.Google Scholar
Tulloch, IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 1997; 49(1 Suppl 1): S58–S62.CrossRefGoogle ScholarPubMed